Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 46%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc. is positioned for positive growth due to its innovative pipeline, particularly with icotrokinra, which has demonstrated a consistent clinical response improvement in inflammation and immunology over extended periods. The company’s drug candidate is expected to capture market share previously held by Otezla, bolstered by its leading efficacy and favorable safety profile, which could translate into substantial revenue growth within the milder disease segments. Furthermore, Protagonist's robust business development track record and anticipated momentum from clinical catalysts set for 2025 suggest a promising outlook for the company's future financial performance.

Bears say

Protagonist Therapeutics Inc faces significant financial risks stemming from industry-standard uncertainties, including potential negative outcomes from ongoing clinical trials and regulatory challenges, which may hinder the development and approval of their product candidates. Additionally, the company is exposed to dilution risk due to future cash needs, compounded by pricing reform pressures that could impact revenue generation in a competitive and increasingly price-sensitive market. Despite having proprietary technology and a focused pipeline, these overarching vulnerabilities contribute to a negative outlook for the company's stock performance.

Protagonist Therapeutics (PTGX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 46% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 13 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.